Skip to main content
Donate

Our Chief Operating Officer joins the White House Clinical Trials Forum

Today, our COO Ryan Fischer will join the White House Clinical Trials Forum organized by the White House Office of Science & Technology Policy.

The meeting convenes key health leaders, advocates, physicians, researchers, and administration officials to discuss challenges and identify new federal and private actions to improve clinical trial participation and access and foster equity in biomedical research.

Goals for the forum include:

  • Sharing developments from the Biden- Harris Administration and learning from one another to accelerate progress;

  • Elevating best practices for people-centered clinical trial design and incorporating the expertise of clinical trial participants as partners in research; and

  • Building on the momentum of recent progress to address shared challenges in expanding access to and participation in clinical trials.

We are excited Angelman syndrome will be represented at the forum. You can listen to the opening discussion from 10:00-11:00am ET here.

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.